FDA Import Alert 66-80: What GLP-1 API Buyers Should Verify in 2026

1. What Import Alert 66-80 is, and what the Aug. 21 update means

FDA's general import-alert guidance explains that detention without physical examination, or DWPE, allows the agency to detain a product offered for entry without first testing or physically examining that shipment when the product appears to violate U.S. requirements.

Import Alert 66-80 applies that mechanism to GLP-1 receptor agonist bulk drug substances and APIs.

The GLP-1 API Green List was established on Sept.

5, 2025.

The current Import Alert page is dated Aug. 21, 2026 and describes a major revision to its guidance, Green List entries and product codes.

That distinction matters: this is a current update to an existing control, not the creation of a new import program in August 2026.

The alert says divisions may detain GLP-1 API shipments offered for U.S. entry except for products and firms identified on the Green List.

Because the list is tied to facilities and associated products and may change, a screenshot, an old letter or a company-level statement is not enough for a current shipment decision.

2. Why FDA is putting physical-site identity and records at the center

FDA states that it conducted onsite inspections and remote regulatory assessments of 48 GLP-1 API sites in the U.S. supply chain.

According to the current alert, 21% were noncompliant under the cited provisions because records provided evidence of noncompliance or because a firm did not respond to a records request within the required time.

The agency also describes a pattern in which sites registered as GLP-1 API manufacturers, offered material for import, declined to answer records requests and then deregistered within a short period.

For a procurement or quality team, the practical issue is therefore not only whether a seller can name a molecule.

It is whether the legal entity, physical manufacturing site, product scope and supporting records remain consistent through the transaction.

Green List status should be checked on the live FDA page immediately before a material import or regulatory decision.

Inclusion reflects FDA's evaluation of recent evidence for the listed facility and associated product scope; it does not establish marketing authorization or eliminate batch-, route-, importer- and intended-use review.

3. Reconcile the actual manufacturer, label, batch and supply-chain roles

For requests to be added to the Green List, FDA lists records identifying all physical manufacturing sites, examples of container labels and information about customers such as shippers, consignees and importers.

It also asks for the names and addresses of contract laboratories used for release testing.

Together, these fields form a traceability chain that can be compared across qualification documents.

A May 2026 FDA warning letter illustrates why that chain matters.

The letter describes semaglutide API purchased from another source, repackaged and relabeled under a different manufacturer identity, with changed manufacturing and retest dates.

It also describes a voluntary recall and requests for remediation of supplier qualification and quality-unit oversight.

The findings apply to that firm and those facts, but they show the risk of accepting labels or certificates without reconciling the actual manufacturing history.

A buyer-side review should therefore compare the quotation, quality agreement, label, CoA, batch identifier, physical site, contract laboratory and shipping documents.

Any unexplained change in manufacturer, lot number, manufacture date, retest date, shipper or consignee should stop the review until the discrepancy is resolved and documented.

4. Connect the CoA to specifications, methods, stability and starting materials

FDA's petition examples include the CoA that would accompany each lot and copies of CoAs for the last ten GLP-1 API lots, or all lots when fewer than ten have been manufactured.

The same section asks for release specifications and testing methods, including scientific justification for impurities, potency and microbial attributes when an API is intended for use in an injectable drug product.

The list continues with stability protocols and summary results, starting-material specifications and testing reports, and method validation or compendial-method verification.

A CoA is therefore one output within a larger analytical control system.

It does not, by itself, establish that the method is suitable, the acceptance criteria are justified or the retest period is supported.

These examples are written for FDA review in the Green List petition context.

They should not be treated as a claim that every buyer is entitled to receive every record publicly.

A qualified project should define which summaries, reports or controlled data-room documents are needed, who can review them, and what confidentiality terms apply.

5. Review the process and quality system behind the released batch

The alert's examples also include process validation protocols and reports, a Master Batch Record, the latest manufacturing batch record, and equipment lists with shared or dedicated status and qualification dates.

It also lists OOS results and investigations, relevant SOPs, the quality-unit organization chart, and five-year summaries of complaints, adverse events, recalls and returns.

The May 2026 warning letter separately discusses distribution before adequate process validation, unsupported retest dates and deficiencies in cleaning validation for equipment used in peptide API manufacture.

Those observations should not be generalized to other sites, but they underline a core qualification principle: a passing release result must be interpreted alongside process reproducibility, equipment controls, stability support, deviation history and quality-unit disposition.

For complex peptide APIs, buyers should also define which process-specific impurity risks, shared-equipment controls, cleaning limits, analytical detectability and change-control triggers need to be reviewed for the exact molecular form and supply route in scope.

6. A practical GLP-1 API pre-inquiry evidence checklist

Before requesting a quotation or beginning a supplier qualification, align the commercial request with the regulatory and evidence scope.

The following questions turn the import-alert themes into a structured first review without treating the article as legal advice or a substitute for an importer, quality unit or regulatory counsel.

A common failure is to begin with price and delivery, then try to reconstruct the manufacturing site and evidence chain after commercial expectations are already set.

Reversing that order usually produces a shorter, more useful first conversation: establish the exact product and site first, then ask what evidence is available for the batch and intended U.S. route.

• What is the exact molecule, chemical form, supplied form, specification and legal product category?
• Which physical site performs synthesis, purification, isolation, packaging, labeling and release, and which steps are subcontracted?
• What exact facility-and-product scope appears on the current FDA Import Alert page, and on what date was it rechecked?
• Can the batch label and CoA be reconciled to the actual manufacturer, site, lot, manufacture date and supported retest date?
• Which release methods, method-validation records, stability data and starting-material controls support the requested specification?
• What process-validation, cleaning, change-control, deviation and OOS information is appropriate for the project stage?
• Who will act as shipper, importer, consignee and regulatory owner for the intended destination and use?
• Which evidence can be reviewed under confidentiality, who owns approval and when must the status be checked again?

7. Keep import status, compounding rules and product authorization separate

Import Alert 66-80 addresses the entry of covered bulk drug substances based on the appearance of a violation.

FDA's separate compounding materials address when a compounded drug may qualify for statutory exemptions and the restrictions that apply when approved products are commercially available.

These are related supply-chain questions, but they are not interchangeable decisions.

Likewise, appearance on a Green List does not establish marketing authorization for a finished product, authorize a particular compounded use or transfer regulatory status to an API seller.

Molecule identity, manufacturing site, batch evidence, importer responsibilities, intended use and destination-market eligibility must be confirmed separately.

The durable procurement lesson is simple: start with the exact product and site, then connect the batch record, analytical evidence, quality system and import role before commercial timing is discussed.

A molecule name alone is not a qualified supply brief.

The live FDA Import Alert page and linked sources were reviewed on Aug.

25, 2026.

Because Import Alert entries and product scope can change, readers should return to the current FDA record before relying on the status for a shipment or qualification decision.